424 related articles for article (PubMed ID: 18471709)
1. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
[TBL] [Abstract][Full Text] [Related]
3. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
4. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.
Brody JR; Costantino CL; Berger AC; Sato T; Lisanti MP; Yeo CJ; Emmons RV; Witkiewicz AK
Cell Cycle; 2009 Jun; 8(12):1930-4. PubMed ID: 19448397
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
Wobser M; Voigt H; Houben R; Eggert AO; Freiwald M; Kaemmerer U; Kaempgen E; Schrama D; Becker JC
Cancer Immunol Immunother; 2007 Jul; 56(7):1017-24. PubMed ID: 17195079
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells.
Cheng CW; Shieh PC; Lin YC; Chen YJ; Lin YH; Kuo DH; Liu JY; Kao JY; Kao MC; Way TD
J Agric Food Chem; 2010 Jan; 58(2):887-94. PubMed ID: 19928918
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo.
Iwamoto N; Ito H; Ando K; Ishikawa T; Hara A; Taguchi A; Saito K; Takemura M; Imawari M; Moriwaki H; Seishima M
Liver Int; 2009 Feb; 29(2):277-83. PubMed ID: 18397228
[TBL] [Abstract][Full Text] [Related]
9. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
10. Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses.
Yu G; Dai H; Chen J; Duan L; Gong M; Liu L; Xiong P; Wang CY; Fang M; Gong F
J Gene Med; 2008 Jul; 10(7):754-61. PubMed ID: 18452241
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
[TBL] [Abstract][Full Text] [Related]
13. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study.
Niinisalo P; Oksala N; Levula M; Pelto-Huikko M; Järvinen O; Salenius JP; Kytömäki L; Soini JT; Kähönen M; Laaksonen R; Hurme M; Lehtimäki T
Ann Med; 2010; 42(1):55-63. PubMed ID: 19941414
[TBL] [Abstract][Full Text] [Related]
14. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy.
Inaba T; Ino K; Kajiyama H; Shibata K; Yamamoto E; Kondo S; Umezu T; Nawa A; Takikawa O; Kikkawa F
Gynecol Oncol; 2010 Jun; 117(3):423-8. PubMed ID: 20350764
[TBL] [Abstract][Full Text] [Related]
16. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma.
Maneechotesuwan K; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Yaikwawong M; Barnes PJ; Wongkajornsilp A
J Allergy Clin Immunol; 2009 Jan; 123(1):239-48. PubMed ID: 19058839
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model.
Källberg E; Wikström P; Bergh A; Ivars F; Leanderson T
Prostate; 2010 Sep; 70(13):1461-70. PubMed ID: 20687219
[TBL] [Abstract][Full Text] [Related]
18. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-dioxygenase in tumor induced tolerance.
Liu XQ; Wang X
Chin Med J (Engl); 2009 Dec; 122(24):3072-7. PubMed ID: 20137504
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
Hiraoka N; Onozato K; Kosuge T; Hirohashi S
Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
